Corticotropin
As of the edition of 20 October 2026, Corticotropin is a drug: marketed, first approved in 1982 (US); acts on MC2R; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Unknown
- Brand name
- Acth
- First approved
- 1 January 1982 (US)
- Approvals on record
- 13 in 1 region
- Holder of the most recent approval
- Byk-Mallinckrodt CIL; 6 holders in all
- Registered trials
- 82, 23 stopped early
- Disease areas
- Immune system; Nervous system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Eye
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Corticotropin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MC2R | Adrenocorticotropic hormone receptor | Q01718 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 18 | 6 | 0 | 2 |
| Phase 1 | 4 | 3 | 0 | 0 |
| Phase 2 | 13 | 6 | 2 | 4 |
| Phase 3 | 9 | 5 | 1 | 1 |
| Phase 4 | 38 | 20 | 0 | 16 |
| All trials | 82 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Byk-Mallinckrodt CIL | Acquired holder and Lead sponsor of trials | 2011 to now |
| ANI Pharmaceuticals | Acquired holder | 2017 to now |
| Sanofi | Later holder | 2024 to now |
| Organics Lagrange | Later holder | |
| Organon | Later holder | |
| Pfizer | Applicant and Earlier holder |